Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 08, 2025 06:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress

Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patientsSupports therapeutic potential of ITM’s proprietary targeted radiotherapeutic agentAbstract receives...